Bear of the Day: Bayer (BAYRY)

We are concerned about Bayer’s (BAYRY) disappointing performance of the CropScience segment in the most recent quarter. Moreover, the delay in approval of Xarelto also concerns us.

Furthermore, the failure of Nexavar to prolong the overall survival in patients suffering from advanced non-squamous non-small cell lung cancer (NSCLC) in a late-stage study is a setback for the company. The competitive environment in which Bayer operates is a further challenge for the company.

Given these factors, we downgrade the stock to Underperform from Neutral with a price target of $54.00.

Zacks Investment Research

About Zacks Investment Research 1767 Articles

Zacks Investment Research is one of the most highly regarded firms in the investment industry. In 1978 Zacks originated the concept of utilizing earnings estimates revisions to make profitable investment decisions. Zacks offers multiple investment products and services to help investors achieve superior returns.


Be the first to comment

Leave a Reply

Your email address will not be published.